OR WAIT null SECS
October 7, 2016
The market size for gastrointestinal therapeutics is set to grow from $35.7 billion in 2015 to $48.4 billion by 2022, representing a compound annual growth rate of 4.45%, according to GBI Research.
The company’s latest report states that although the market has recently been hit by the patent expirations of a number of the leading gastrointestinal products, such as Nexium and Remicade, the approval of new drugs, as well as rising prevalence, are expected to drive considerable growth.
In terms of the gastrointestinal pipeline, there are 937 products in active development, most of which are small molecules and biologics. The therapy area is highly active and has the seventh-largest pipeline across the pharma industry, with more active pipeline products than therapy areas such as respiratory, ophthalmology, and dermatology.